People with multiple sclerosis (MS) and other conditions who use Mallinckrodt‘s treatment Acthar Gel (repository corticotropin injection) now have a self-injection option, the company said. Acthar Gel Single-Dose Pre-filled SelfJect is available in two dosages — 40 USP units/0.5 ml and 80 USP units/1.0 mL — that…

ANI Pharmaceuticals has announced the full U.S. commercial availability of Cortrophin Gel (repository corticotropin injection), an injectable therapy approved for managing acute relapses in people with multiple sclerosis (MS) and other autoimmune disorders. “Patients with certain chronic autoimmune conditions often need additional treatment options,” Mary Pao Seideman, MD,…

Imaging Brain Metabolites May Help Diagnose, Monitor MS Have you ever heard of magnetic resonance spectroscopic imaging, or MRSI? I hadn’t until I read this story. It’s a technique that in concept allows a radiologist to see metabolites in the brain. Metabolites are small molecules that are produced during…

Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…

Cortrophin Gel (repository corticotropin injection), an injectable gel medication approved for acute flares in multiple sclerosis (MS) and other chronic autoimmune diseases, is now available through the AllianceRx Walgreens Prime specialty pharmacy to patients living in the U.S. First approved by the U.S. Food and Drug Administration (FDA)…

Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines This research adds more evidence to studies that have already shown that certain disease-modifying therapies reduce the effectiveness of COVID-19 vaccines. Those DMTs include Kesimpta (ofatumumab) and Ocrevus (ocrelizumab), plus rituximab, another anti-CD20 vaccine, that is sometimes used…

There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive corticosteroids for the treatment of multiple sclerosis (MS) and other diseases, according to a new review paper. “We found no evidence where it was a conclusive slam dunk that…

Analysis Finds Acthar Gel Cost-effective for MS Relapses I’ve seen social media posts from people with MS who use Acthar Gel and report that it helps with their spasticity. The gel, which is a shot, not an ointment, prompts the body to creates cortisol, a steroid hormone that helps…

Acthar Gel (repository corticotropin injection) was found to be a cost-effective treatment for people with multiple sclerosis (MS) experiencing a relapse, according to an economic analysis. Notably, the economic value of Acthar Gel was greater than that of alternative treatments — plasmapheresis and intravenous immunoglobulin — from the…

The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the U.S. Food and Drug Administration (FDA). In…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum post “MS Treatment Eases Flare-up Symptoms After 2 Months” from Oct.

ANI Pharmaceuticals is asking the U.S. Food and Drug Administration (FDA) for the right to reintroduce in the U.S. market its Cortrophin Gel (repository corticotropin injection, 80 U/ml) to treat acute exacerbations in multiple sclerosis (MS) and other diseases. Currently, the only repository corticotropin injection available in…

Acthar Gel (repository corticotropin injection) leads to significant improvements after two months of use in people with multiple sclerosis (MS) still having acute relapses despite treatment, and who failed to respond to other high-dose corticosteroids, topline data from an observational study show. The gel’s developer, Mallinckrodt Pharmaceuticals, also…

Acthar Gel (repository corticotropin injection) is more effective for treating flares in multiple sclerosis (MS) than other alternatives, including intravenous immunoglobulin or plasmapheresis, a claims-based study from Mallinckrodt Pharmaceuticals reports. The study “Treatment Effectiveness for Resolution of Multiple Sclerosis…

Acthar Gel (repository corticotropin injection) eased flare-up symptoms in patients with multiple sclerosis (MS) experiencing relapses, top-line data from an observational registry study shows. Acthar Gel, a medication developed and marketed by Mallinckrodt Pharmaceuticals, is a compound that enhances the production of steroids in the…

In this column, I take a look at more exciting research from the ECTRIMS2019 conference this month. #ECTRIMS2019 – Ozanimod’s ‘Key Advantages’ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen This year we’ve seen the approval of two new multiple sclerosis treatments in the United…

Late-line use of H.P. Acthar Gel to treat relapses in adults with multiple sclerosis (MS) is linked with lower costs than other therapies used after an initial poor response, including plasmapheresis and intravenous immunoglobulin, according to an analysis by Mallinckrodt Pharmaceuticals, the treatment’s marketer. George Wan, PhD, Mallinckrodt’s vice president and…

In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Acne Therapy Reduces Rate of Multiple Sclerosis Progression, Canadian Study Reports At first glance, the headlines about this drug announced what seemed to be…

Mallinckrodt has enrolled its first relapsing multiple sclerosis (MS) patient into a Phase 4 clinical trial (NCT03126760) with H.P. Acthar Gel (Repository Corticotropin Injection) to see if the therapy can help treat relapse symptoms in patients who did not respond to high-dose steroids. If successful, the trial might resolve…

Clinical results presented at the recent Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meeting in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses is associated with beneficial outcomes. The gel, according to its producer, is also available at a lower price than other frequently used…